OSMI-1 | O-GlcNAc Transferase Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1681056-61-0
Formula :	C₂₈H₂₅N₃O₆S₂
M.W :	563.64
SMILES Code :	O=C(N(CC1=CC=CO1)CC2=CC=CS2)[C@@H](C3=CC=CC=C3OC)NS(=O)(C4=CC5=C(NC(C=C5)=O)C=C4)=O
MDL No. :	MFCD30187585
InChI Key :	IYIGLWQQAMROOF-HHHXNRCGSA-N
Pubchem ID :	118634407

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338

Huh7-HBV1.3 cells	20 μM	12 hours	Inhibited YTHDF2 O-GlcNAcylation and downregulated MCM2 and MCM5 mRNA levels	PMC9918532
HepG2-HBV1.3 cells	20 μM	12 hours	Inhibited YTHDF2 O-GlcNAcylation and downregulated MCM2 and MCM5 mRNA levels	PMC9918532
Neuroblastoma N2a cells	60 μM	12 hours	Inhibited O-GlcNAc levels, significantly impaired cell viability, and accelerated apoptosis	PMC10943090
AML12 cells	20 μM	15 hours	To evaluate the effect of OSMI-1 on normal hepatocytes, results showed no significant impact on apoptosis in AML12 cells.	PMC7693581
HepG2 cells	20 μM	15 hours	To evaluate the effect of OSMI-1 on apoptosis in HepG2 cells, results showed OSMI-1 significantly enhanced DOX-induced apoptosis.	PMC7693581
NK92 cells	25 µM	24 hours	OSMI-1 treatment led to decreased expression of NKG2D and NKG2A, increased expression of KIR2DL1, and significantly reduced cytotoxicity in NK92 cells.	PMC9036377
Primary NK cells	25 µM	24 hours	Inhibition of O-GlcNAcylation resulted in decreased expression of NK cell receptors (NKG2D, NKG2A, NKp44), cytokines (TNF-α, IFN-γ), granulysin, soluble Fas ligand, perforin, and granzyme B in NK cells, leading to reduced cytotoxic function.	PMC9036377
HepG2 cells	20 μM	24 hours	The combination treatment of OSMI-1 and TRAIL significantly increased the apoptosis rate in HepG2 cells.	PMC8539180
HCT116 human colon cancer cells	20 μM	24 hours	OSMI-1 significantly increased TRAIL-mediated apoptosis by increasing the expression of the cell surface receptor DR5. ROS-induced ER stress by OSMI-1 not only upregulated CHOP-DR5 signaling but also activated JNK, resulting in a decrease in Bcl2 and the release of cytochrome c from mitochondria.	PMC8539180
IPAH PAECs:PASMCs	25 µM	24 hours	To assess the effect of OGT inhibition on vascular sprouting in a 3D co-culture model, results showed that OSMI-1 reduced sprouts and sprout length in IPAH spheroids.	PMC6941156
IPAH PAECs	25 µM	24 hours	To assess the effect of OGT inhibition on SP1 O-GlcNAc modification, results showed that OSMI-1 reduced O-GlcNAc modification levels on SP1 in IPAH PAECs.	PMC6941156
Non-IPF lung fibroblasts	25 μM	24 hours	To examine the blocking effect of OSMI-1 on TGF-β1-induced downregulation of Cox2 and Hmox1. Results showed that pretreatment with OSMI-1 attenuated the inhibitory effects of TGF-β1 on Cox2 and Hmox1.	PMC10945079
LNCaP-AI cells	20 μM	72 hours	OSMI-1 significantly inhibited the proliferation of LNCaP-AI cells.	PMC11542072
Primary IPF lung fibroblasts	25 μM	24 hours	To investigate the effects of OSMI-1 on the expression of Cox2 and Hmox1. Results showed that Cox2 and Hmox1 expression at both mRNA and protein levels were significantly increased following OGT inhibition.	PMC10945079
Chondrocytes	20 μM	3 days	Inhibiting O-GlcNAcylation, partially mitigating compression-induced hypertrophic differentiation of chondrocytes	PMC11890221
Human iPSC-derived cardiomyocytes	50 μM	30 minutes	Inhibition of GlcNAcylation, prevented Hi-Glu-induced ROS production	PMC7210078
Adult mouse ventricular myocytes	50 μM	30 minutes	Inhibition of GlcNAcylation, prevented ROS induction in response to either Hi-Glu or Thm-G	PMC7210078
Bone marrow-derived macrophages (BMMs)	5 μM	4 days	OSMI-1 dose-dependently reduced the number of TRAP-positive mature osteoclasts and actin belt formation, and decreased the overall O-GlcNAcylation level with a significant and concomitant decline in NFATc1 levels during osteoclast differentiation.	PMC8396330
HCT116 cells	5, 10, 20 μM	48 hours	OSMI-1 significantly increased the expression of LC3-II and the ratio of LC3-II/LC3-I, indicating an increase in autophagic flux.	PMC10239094
RLE-6TN cells	1 μM	48 hours	To evaluate the effect of OSMI-1 on the proliferation of hyperoxia-induced RLE-6TN cells. Results showed that OSMI-1 treatment for 48 h increased cell proliferation by 41.1%.	PMC9841680
Human monocyte derived dendritic cells (moDCs)	20 µM	6 days	Investigated the effects of OGT inhibitor OSMI-1 on the differentiation and maturation process of moDCs, showing modulation of AKT and MEK/ERK pathways, altered expression of surface markers, and cytokine secretion.	PMC8699345
HCT116 cells	10 μM	6 hours	To study the effect of OSMI-1 on OGT intron retention, results showed that OSMI-1 treatment increased OGT mRNA levels.	PMC5588854
293A-TOA cells	10 μM	6 hours	To study the effect of OSMI-1 on OGT intron retention, results showed that OSMI-1 treatment increased the efficiency of β-OGT splicing.	PMC5588854
IPAH PAECs	25 µM	6 hours	To assess the effect of OGT inhibition on endothelial tube formation, results showed that OSMI-1 significantly reduced the number of tube-like structures and tube length in IPAH PAECs.	PMC6941156
HEK293 cells	25 μM	6 hours	Metabolic labeling and pull-down assays confirmed that OSMI-1 treatment prevented O-GlcNAcylation of p38.	PMC9988579
Neonatal rat ventricular myocytes (NRVMs)	25 μM	6 hours	Inhibited OGT activity, reduced protein O-GlcNAcylation by 50%, and induced a 3.9-fold increase in p38 phosphorylation.	PMC9988579

Nude mice	LNCaP-AI xenograft model	Intravenous injection	1 mg/kg	Administered every other day for 4 weeks	OSMI-1 significantly inhibited the growth of LNCaP-AI xenograft tumors.	PMC11542072
Nude mice	HCT116 xenograft model	Intravenous injection	1 mg/kg	Once daily for 21 days	The combination treatment of OSMI-1 and TRAIL significantly reduced tumor volume and weight by enhancing ER stress response and inhibiting NF-κB signaling.	PMC8539180
Nude mice	HepG2 xenograft model	Intravenous injection	1 mg/kg (OSMI-1) and 0.1 mg/kg (DOX)	Once every 3 days for 3 weeks	To evaluate the effect of combination therapy with OSMI-1 and DOX on tumor growth, results showed significant inhibition of tumor growth.	PMC7693581
BALB/c nude mice	HCT116 xenograft model	Intravenous injection	1 mg/kg/day	Once daily for 28 days	Combination treatment significantly inhibited the growth of HCT116 xenograft tumors, with a significant reduction in tumor volume and weight.	PMC10239094
C57BL/6 male mice	LPS-induced bone loss model	Subcutaneous injection	10 mg/kg/day	Once daily for 6 days	OSMI-1 significantly reduced the number of TRAP-specific mature osteoclasts in the calvarial surfaces and sections.	PMC8396330
Sprague Dawley rats	Hyperoxia-induced neonatal rat model of bronchopulmonary dysplasia	Intraperitoneal injection	10 mg/kg/day	Once daily for 14 days	To evaluate the effect of OSMI-1 on hyperoxia-induced alveolarization in neonatal rats. Results showed that OSMI-1 promoted alveolarization and increased RAC values.	PMC9841680
Sprague-Dawley (SD) rats	Temporomandibular joint (TMJ) degeneration model	Intra-articular injection	10 mg/ml	Once daily for the duration of the experiment	Inhibiting O-GlcNAcylation, mitigating FMR-induced hypertrophic differentiation of chondrocytes	PMC11890221
Mouse	REM sleep deprivation model	Intraperitoneal injection	100 µg/kg	Single dose, lasting 2 hours	OSMI-1 inhibited OGT activity, resulting in impaired memory function and inhibition of FC-induced PKA/CREB activation.	PMC8804064
Mice	Xenograft tumor model	Intraperitoneal injection	20 mg/kg	Once daily for 24 days	To study the tumor growth of ISS-deleted cells under OGA inhibition, results showed that tumor growth of ISS-deleted cells was compromised.	PMC5588854
NOD/SCID mice	Humanized angiogenic mouse model	Collagen implants	25 µM	Single administration, lasting 7-14 days	To assess the effect of OGT inhibition on in vivo vascularization, results showed that OSMI-1 reduced vascularization in IPAH PAECs.	PMC6941156
HBV-transgenic mice	DEN/CCl4-induced HCC model	Intraperitoneal injection	5 mg/kg	Twice a week for 12 weeks	Inhibited YTHDF2 O-GlcNAcylation and decelerated liver tumorigenesis	PMC9918532
Mice	Stx2a intoxication model	Injection	Daily injection	Daily administration starting from the day before intoxication	OSMI-1 significantly protected mice from weight loss, elevated kidney injury markers, and death	PMC8749490

{[proInfo.proName]}

CAS No.: 1681056-61-0

{[proInfo.proName]}

CAS No.: 1681056-61-0

Alternative Products

Product Details of OSMI-1

Safety of OSMI-1

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.77mL 0.35mL 0.18mL	8.87mL 1.77mL 0.89mL	17.74mL 3.55mL 1.77mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed